Share your videos with the world

Sign Up | Log In | Help  

   
 
Related Tags: gene  therapy  hemophilia  b  bleeding  disorder  st  jude  childrens  research  hospital  university  college  london  multivu  46766  emdeon  edge  payment  integrity  cost  management  claim  fraud  solutions  healthcare  multivu  48121  elekta  agility  mlc  radiation  therapy  innovation  cancer  treatments  oncology  technology  multivu  55638  emdeon  atigeo  big  data  ytics  patient  care  payment  revenue  management  information  exchange  healthcare  multivu  59755  copper  development  greence  sustainability  arizona  health  sciences  innovative  construction  architects  multivu  61608  antimicrobial  copper  clinical  trial  hospitals  healthcare  acquired  infections  icu  patients  health  multivu  61120  epilepsy  treatment  upsher  smith  practice  management  billing  codes  neurology  doctors  medicine  healthcare  multivu  58062  emdeon  clinical  exchange  health  information  solutions  care  business  technology  healthcare  multivu  48120  slo-niacin  upsher-smith  heart  health  cholesterol  cardiologists  niacin  dietary  supplement  hdl  multivu  58806  avon  anew  clinical  pro  line  eraser  treatment  anti  aging  wrinkles  skincare  multivu  52897  siro  clinpharm  clinical  research  medical  drug  development  trial  study  management  business  health  multivu  58672  asuragen  fragilex  syndromes  autism  xpansion  interpreter  genetic  test  pregnancy  children  women  health  multivu  60719 
Search // clinical
Results 37-48 of 101 for ' clinical ' (0 seconds)
Emdeon Inc., a leading provider of healthcare revenue and payment cycle management and clinical information exchange solutions, today announced the expansion of Emdeon Clinical Exchange™, its technology-enabled solution designed to improve business and clinical outcomes and care continuity. Emdeon Clinical Exchange encompasses products and services that are designed to unite healthcare communities. Today, hospitals, physicians, labs, payers and pharmacies use Emdeon’s leading healthcare information network to securely exchange health information over six billion times annually. These healthcare stakeholders are demanding greater connectivity to each other and the ability to facilitate comprehensive, end-to-end clinical information exchange. To view Multimedia News Release, go to http://www.multivu.com/mnr/48120-emdeon-expands-clinical-information-exchange-capabilities
Categories // Business  Science and Technology 
Added: 4469 days ago by MultiVuVideos
Runtime: 1m47s | Views: 2362 | Comments: 1
Not yet rated
 

 

 

Avon celebrated the brand’s latest innovation, ANEW Clinical Pro Line Eraser Treatment, with flash mobs coast to coast in five cities, including New York, Chicago, Atlanta, Dallas and Los Angeles. Professional ballroom dancer Karina Smirnoff led the moves and wowed the crowd in Los Angeles. Avon Representatives in all cities joined in on the flash mobs and distributed tens of thousands of samples of ANEW Clinical Pro Line Eraser Treatment, which launches this month across the country. “I can never turn down an opportunity to dance—especially when it’s celebrating such an exciting new innovation like Pro Line Eraser Treatment,” says Smirnoff. “I’m so thrilled to be a part of this big moment for Avon and spending time with the Representatives and fans.” To view Multimedia News Release, go to http://www.multivu.com/mnr/52897-avon-anew-clinical-pro-line-eraser-treatment-skincare-dermatology
Categories // Fashion and Lifestyle 
Added: 4458 days ago by MultiVuVideos
Runtime: 1m20s | Views: 2012 | Comments: 0
Not yet rated
 

 

 

SIRO Clinpharm, a leading full service clinical research organization, unveiled its new brand identity on Friday. The new look affirms the recent transformation in the company’s business strategy. “With the vast experience garnered over the past 16 years, SIRO was set to take a leap forward. With its customer centric leadership, we have built depth in various areas of competencies, leveraging our 4 pillars – people, processes, technologies and solutions,” said Dr. Gautam Daftary, founder and chairman, SIRO Clinpharm. To view Multimedia News Release, go to http://www.multivu.com/mnr/58672-SIRO-Clinpharm-unveils-new-brand-identity
Categories // Business  Science and Technology 
Added: 4322 days ago by MultiVuVideos
Runtime: 1m34s | Views: 1999 | Comments: 1
Not yet rated
 

 

 

Asuragen Inc., a leading molecular diagnostics company, today announced results from a study demonstrating that a new molecular test called Xpansion Interpreter® can improve the determination of a woman’s risk of having a child with fragile X syndrome, the most common inherited cause of intellectual disability and autism, compared to existing risk measures. The Xpansion Interpreter Test is based on a technology breakthrough that reveals both the number and position of “interrupting” DNA sequences in the fragile X gene of the mother and more accurately estimates the likelihood that her child will have fragile X syndrome. The study will be published in the April issue of the American Journal of Medical Genetics and presented today at the 2013 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting in Phoenix, AZ. To view Multimedia News Release, go to http://www.multivu.com/mnr/60719-asuragen-xpansion-interpreter-xi-test-data-fragile-x-syndrome-autism
Added: 4263 days ago by MultiVuVideos
Runtime: 3m22s | Views: 1988 | Comments: 0
Not yet rated
 

 

 

Amway North America today launched an online personalized health assessment to simplify the product selection process for consumers. The NUTRILITE® Supplement Recommender is an easy-to-use scientifically-based tool that identifies tailored options for supplementation. The Supplement Recommender was developed by a Nutrilite team of research and clinical scientists based on the world's No. 1 selling vitamins and dietary supplements brand’s product portfolio.* It identifies health, lifestyle and behavior measures associated with nutrition and health outcomes to generate three primary individualized supplement recommendations and up to nine other product options for optimal health. To view Multimedia News Release, go to http://www.multivu.com/mnr/61025-amway-personalized-health-assessment-nutrilite-supplement-recommender
Categories // Business  Science and Technology 
Added: 4045 days ago by MultiVuVideos
Runtime: 1m19s | Views: 1854 | Comments: 1
Not yet rated
 

 

 

Reproductive Medicine Associates of New Jersey (http://www.rmanj.com) today presented interim findings from its BEST (Blastocyst Euploid Selective Transfer) trial, the first well-controlled clinical trial comparing in vitro fertilization (IVF) pregnancy rates in a group of women receiving a single embryo transfer (SET) with comprehensive chromosome screening (CCS) with a group receiving traditional morphology-based double embryo transfer (DET). The findings were presented at the American Society for Reproductive Medicine 68th Annual Meeting in San Diego, October 20-24, 2012. To view Multimedia News Release, go to http://www.multivu.com/mnr/58883-rmanj-best-trial-results-ivf-pregnancy-rates-women-asrm-annual-meeting
Added: 4410 days ago by MultiVuVideos
Runtime: 2m26s | Views: 1760 | Comments: 1
Not yet rated
 

 

 

Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today the initiation of its Phase III clinical program called Cdiffense to evaluate the safety, immunogenicity and efficacy of an investigational vaccine for the prevention of primary symptomatic Clostridium difficile infection (CDI). Clostridium difficile (C. diff) is a potentially life-threatening, spore-forming bacterium that causes intestinal disease. The risk of C. diff increases with age, antibiotic treatment and time spent in hospitals or nursing homes, where multiple cases can lead to outbreaks. The investigational vaccine is designed to help protect at-risk individuals from C. diff, which is emerging as a leading cause of life-threatening, healthcare-associated infections (HAIs) worldwide. To view the Multimedia News Release, go to http://www.multivu.com/mnr/62652-sanofi-pasteur-initiates-phase-iii-study-of-investigational-vaccine
Categories // Business  Science and Technology 
Added: 4126 days ago by MultiVuVideos
Runtime: 1m59s | Views: 1674 | Comments: 1
Not yet rated
 

 

 

Interim clinical results from Project IMPACT: Diabetes, announced today by the American Pharmacists Association (APhA) Foundation, show statistically significant decreases in A1C or blood sugar levels, LDL cholesterol, systolic blood pressure and Body Mass Index (BMI), which are all recognized standards of diabetes care. Participating patients in 25 communities who experienced improved outcomes encompass almost every socioeconomic class, insurance status and ethnicity. To view Multimedia News Release, go to http://www.multivu.com/mnr/62268-american-pharmacists-association-apha-foundation-project-impact-diabetes
Categories // People and Blog 
Added: 4045 days ago by MultiVuVideos
Runtime: 5m20s | Views: 1595 | Comments: 1
Not yet rated
 

 

 

Diabetes experts met and determined that some self-monitoring blood glucose (SMBG) systems, despite meeting accuracy standards at the time of U.S. Food and Drug Administration (FDA) clearance, fail to consistently meet accuracy standards once on the market, potentially putting patient health at risk. In a public meeting convened by the Diabetes Technology Society on May 21, 2013, in Arlington, Virginia, leading academic clinicians, clinical chemists, medical device experts, patient advocates and FDA representatives reviewed a growing body of peer-reviewed research demonstrating that the performance of some blood glucose monitors on the market may not be meeting accuracy standards. To view the Multimedia News Release, go to http://www.multivu.com/mnr/61870-diabetes-technology-society-inaccurate-blood-glucose-monitors-risky
Added: 4195 days ago by MultiVuVideos
Runtime: 2m46s | Views: 1563 | Comments: 0
Not yet rated
 

 

 

Three and a half years after beginning a clinical trial which demonstrated the first successful and sustained use of genetically engineered T cells to fight leukemia, a research team from the Perelman School of Medicine at the University of Pennsylvania and the Children’s Hospital of Philadelphia will today announce the latest results of studies involving both adults and children with advanced blood cancers that have failed to respond to standard therapies. The findings from the first 59 patients who received this investigational, personalized cellular therapy, known as CTL019, will be presented during the American Society of Hematology’s Annual Meeting and Exposition in New Orleans. To view Multimedia News Release, go to http://www.multivu.com/mnr/64691-penn-medicine-reports-research-leukemia-patients-cellular-therapy-ctl019
Added: 4000 days ago by MultiVuVideos
Runtime: 6m52s | Views: 1467 | Comments: 1
Not yet rated
 

 

 

Phenogen Sciences, Inc. [www.phenogensciences.com] today announced the immediate availability of BREVAGen™, a predictive risk test for the millions of women at above average risk of developing estrogen-receptor positive breast cancer. This first-in-class, scientifically-validated risk assessment test examines a woman’s clinical risk factors, such as her lifetime exposure to estrogen, combined with scientifically validated genetic markers to determine each patient’s personalized five-year and lifetime risk of developing breast cancer. To view Multimedia News Release, go to http://www.multivu.com/mnr/58399-phenogen-sciences-brevagen-breast-cancer-risk-assessment-test-availability
Added: 4432 days ago by MultiVuVideos
Runtime: 3m56s | Views: 1379 | Comments: 0
Not yet rated
 

 

 

For the millions who suffer from Gastroesophageal Reflux Disease (GERD), a study published today in the New England Journal of Medicine (NEJM) provides clinical evidence of safety and effectiveness for a new, FDA-approved medical device. Torax Medical’s LINX® Reflux Management System was studied in a controlled, prospective, multicenter trial involving 14 U.S. and European medical centers as part of the FDA pre-market approval process. The patients were evaluated before and after treatment to determine the effect of the LINX System on their GERD using pre-defined success criteria, which included reduction of esophageal acid, improvement in quality of life and elimination of reflux medications. To view Multimedia News Release, go to http://www.multivu.com/mnr/60077-torax-medical-linx-reflux-management-system-clinical-study-published
Added: 4291 days ago by MultiVuVideos
Runtime: 4m58s | Views: 1343 | Comments: 0
Not yet rated
 

 

 

Page 4 of 9  |  Go to page     |  ««FIRST «Previous  Next» LAST»»



About Us   |   Help  |   Advertise on ClipMoon   |   Terms of Use   |   Privacy Policy   |   Copyright   |   Contact   |   Link us   |   RSS 
Copyright © 2007-2024 ClipMoon.com. All rights reserved.